Eli Lilly and Humana have teamed up to analyze various data sets to understand disease outcomes, starting with Type 2 diabetes, the companies announced this morning.
BT and Accelrys have expanded their joint efforts to give life sciences researchers access to web-based software tools and data. The companies have combined their respective technologies again to help researchers mine massive data sets from U.K. and U.S. sources for valuable knowledge.
While Big Data is a real problem, it's not a Big Problem. What is a Big Problem, on the other hand, is the challenge of dealing with the diverse variety of (small) data that's needed for decision-making throughout the drug discovery, development, and commercialization life cycles.
The move gives the consulting giant the keys to Newton, MA-based Recombinant Data's growing business that serves the data needs of hospitals, research institutions and healthcare companies.
The Pittsburgh-based health group has tapped Oracle, IBM, Informatica and dbMotion for technology in the $100 million project, which will give clinicians, researchers, administrators and others real-time access to data and analytics, UPMC announced Oct. 1.
Amazon has revealed a new cloud-based service called Glacier for archiving large amounts data on the cheap.
As Sanofi ($SNY) seeks expansion in the fast-growing diabetes market, the Paris-based drugmaker has awarded $100,000 to a group called n4a Diabetes Care Center for designing a system that analyzes Big Data sources to improve diabetes treatment.
The Palo Alto, CA-based startup has announced a cloud-based version of its software for analyzing and visualizing clinical trial data.
The deal comes amid rapid business expansion at Decision Resources, which provides web-based research tools, predictive analytics and other services to drugmakers and other healthcare stakeholders.
Sold on the growing need for data in biopharma, India's Piramal Healthcare has scooped up Decision Resources Group in deal valued at about $635 million.